-
Je něco špatně v tomto záznamu ?
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
RU. Müller, AL. Messchendorp, H. Birn, G. Capasso, E. Cornec-Le Gall, O. Devuyst, A. van Eerde, P. Guirchoun, T. Harris, EJ. Hoorn, NVAM. Knoers, U. Korst, D. Mekahli, Y. Le Meur, T. Nijenhuis, ACM. Ong, JA. Sayer, F. Schaefer, A. Servais, V....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
35134221
DOI
10.1093/ndt/gfab312
Knihovny.cz E-zdroje
- MeSH
- antagonisté antidiuretického hormonu farmakologie terapeutické užití MeSH
- ledviny MeSH
- lidé MeSH
- polycystické ledviny autozomálně dominantní * farmakoterapie MeSH
- tolvaptan terapeutické užití MeSH
- výběr pacientů MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.
Association PolyKystose France Saclay France
Biogem Institute for Molecular Biology and Genetics Ariano Irpino Italy
CECAD University of Cologne Faculty of Medicine and University Hospital Cologne Cologne Germany
Department Genetics University Medical Centre Groningen Groningen The Netherlands
Department of Genetics University Medical Center Utrecht Utrecht The Netherlands
Department of Nephrology 1st Faculty of Medicine General University Hospital Prague Czech Republic
Department of Renal Medicine Aarhus University Hospital Aarhus Denmark
Department of Renal Medicine University College London London UK
Department of Translational Medical Sciences Vanvitelli University Naples Italy
Departments of Clinical Medicine and Biomedicine Aarhus University Aarhus Denmark
Division of Nephrology UCL Medical School Brussels Belgium
Institute of Physiology University of Zurich Zurich Switzerland
Nephrology and Transplantation Department Necker University Hospital APHP Paris France
PKD Familiäre Zystennieren e 5 Bensheim Germany
PKD International Geneva Switzerland
Sheffield Kidney Institute Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018723
- 003
- CZ-PrNML
- 005
- 20220804135041.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ndt/gfab312 $2 doi
- 035 __
- $a (PubMed)35134221
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Müller, Roman-Ulrich $u Department II of Internal Medicine and Center for Molecular Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany $u CECAD, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany $1 https://orcid.org/0000000169100745
- 245 13
- $a An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International / $c RU. Müller, AL. Messchendorp, H. Birn, G. Capasso, E. Cornec-Le Gall, O. Devuyst, A. van Eerde, P. Guirchoun, T. Harris, EJ. Hoorn, NVAM. Knoers, U. Korst, D. Mekahli, Y. Le Meur, T. Nijenhuis, ACM. Ong, JA. Sayer, F. Schaefer, A. Servais, V. Tesar, R. Torra, SB. Walsh, RT. Gansevoort
- 520 9_
- $a Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.
- 650 _2
- $a antagonisté antidiuretického hormonu $x farmakologie $x terapeutické užití $7 D065092
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $7 D007668
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a výběr pacientů $7 D018579
- 650 12
- $a polycystické ledviny autozomálně dominantní $x farmakoterapie $7 D016891
- 650 _2
- $a tolvaptan $x terapeutické užití $7 D000077602
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Messchendorp, A Lianne $u Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Birn, Henrik $u Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark $u Departments of Clinical Medicine and Biomedicine, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Capasso, Giovambattista $u Department of Translational Medical Sciences, Vanvitelli University, Naples, Italy $u Biogem Institute for Molecular Biology and Genetics, Ariano Irpino, Italy $1 https://orcid.org/0000000334698614 $7 xx0114193
- 700 1_
- $a Cornec-Le Gall, Emilie $u University Brest, Inserm, UMR 1078, GGB, CHU Brest, Brest, France
- 700 1_
- $a Devuyst, Olivier $u Institute of Physiology, University of Zurich, Zurich, Switzerland $u Division of Nephrology, UCL Medical School, Brussels, Belgium $1 https://orcid.org/0000000337444767
- 700 1_
- $a van Eerde, Albertien $u Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
- 700 1_
- $a Guirchoun, Patrick $u Association PolyKystose France (PKD France), Saclay, France
- 700 1_
- $a Harris, Tess $u PKD International, Geneva, Switzerland
- 700 1_
- $a Hoorn, Ewout J $u Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands $1 https://orcid.org/0000000287383571
- 700 1_
- $a Knoers, Nine V A M $u Department Genetics, University Medical Centre Groningen, Groningen, The Netherlands
- 700 1_
- $a Korst, Uwe $u PKD Familiäre Zystennieren e.V., Bensheim, Germany
- 700 1_
- $a Mekahli, Djalila $u PKD Research Group, Laboratory of Pediatrics, Department of Development and Regeneration, KU Leuven, Leuven, Belgium $u Department of Pediatric Nephrology and Organ Transplantation, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Le Meur, Yannick $u Department of Nephrology, Hemodialysis and Renal Transplantation, CHU and University of Brest, Brest, France
- 700 1_
- $a Nijenhuis, Tom $u Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboudumc Center of Expertise for Rare Kidney Disorders, Radboud University Medical Center, Nijmegen, The Netherlands $1 https://orcid.org/0000000243757236
- 700 1_
- $a Ong, Albert C M $u Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK $u Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK $1 https://orcid.org/0000000272115400
- 700 1_
- $a Sayer, John A $u Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK
- 700 1_
- $a Schaefer, Franz $u Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Servais, Aude $u Nephrology and Transplantation Department, Necker University Hospital, APHP, Paris, France
- 700 1_
- $a Tesar, Vladimir $u Department of Nephrology, 1st Faculty of Medicine, General University Hospital, Prague, Czech Republic
- 700 1_
- $a Torra, Roser $u Inherited Kidney Diseases Nephrology Department, Fundació Puigvert Instituto de Investigaciones Biomédicas Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain $u REDINREN, Barcelona, Spain $1 https://orcid.org/0000000187142332
- 700 1_
- $a Walsh, Stephen B $u Department of Renal Medicine, University College London, London, UK
- 700 1_
- $a Gansevoort, Ron T $u Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 773 0_
- $w MED00010288 $t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association $x 1460-2385 $g Roč. 37, č. 5 (2022), s. 825-839
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35134221 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135034 $b ABA008
- 999 __
- $a ok $b bmc $g 1822371 $s 1169966
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 37 $c 5 $d 825-839 $e 20220425 $i 1460-2385 $m Nephrology, dialysis, transplantation $n Nephrol Dial Transplant $x MED00010288
- LZP __
- $a Pubmed-20220720
